Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.
about
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisHMG CoA reductase inhibitors (statins) for dialysis patientsHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisRelation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapyJupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens.Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trialsAddressing the Global Burden of Trauma in Major SurgeryEffect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized TrialsBenefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetesTreatment of dyslipidemiaNonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB CouncilIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesImplications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic targetStatins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesionEffects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trialsStatins in Primary Prevention: Uncertainties and Gaps in Randomized Trial Data.The effect of rosuvastatin on inflammation, matrix turnover and left ventricular remodeling in dilated cardiomyopathy: a randomized, controlled trial.Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.Effect of dietary pulse intake on established therapeutic lipid targets for cardiovascular risk reduction: a systematic review and meta-analysis of randomized controlled trialsCan pulses play a role in improving cardiometabolic health? Evidence from systematic reviews and meta-analysesEffect of statins on clinical and molecular responses to intramuscular interferon beta-1a.Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by represPleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.FOS expression in blood as a LDL-independent marker of statin treatment.Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins.Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?Statins for the prevention of stroke: a meta-analysis of randomized controlled trials.Prevalence and incidence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis protocolSex differences in the effectiveness of statins after myocardial infarction.Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.Pitavastatin Reduces Inflammation in Atherosclerotic Plaques in Apolipoprotein E-Deficient Mice with Late Stage Renal Disease.The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress.Metabolic syndrome: the danger signal in atherosclerosis.Lipid-altering effects of a dietary supplement tablet containing free plant sterols and stanols in men and women with primary hypercholesterolaemia: a randomized, placebo-controlled crossover trialStatins are associated with a reduced risk of cholangiocarcinoma: a population-based case-control study.Anti-inflammatory effects of statins beyond cholesterol lowering
P2860
Q24194514-C349B732-2ECC-4FE7-8729-FD9EF67F9439Q24239881-5A837E9C-0910-46A0-A0AD-3EC4297E20B6Q24241472-2B6FC244-3898-4DCC-9B2A-EE24A135CD5CQ24594496-09C823A5-4508-4709-A8F5-B7B1EE395EBCQ24630160-1A7B9946-2031-4EED-A395-5252C84A4485Q26766157-B31CB8AF-0509-405D-B59D-A639AFC4B07FQ26776293-1D31BFEB-ECC5-40EB-9B10-720036F88E57Q26782817-4CA6AE27-6719-4CDF-BE2B-3BFAB250353AQ26797486-D5FF0A68-D929-42EF-AA94-F7EC767525BDQ26853571-ED4F8ACB-6631-43C3-8612-9F1EDC9042ADQ27026114-A2DFD29B-43C8-4D84-8E9B-FAB0DC53FAD4Q28084156-10252921-1648-4761-9814-1099890DD9C7Q28388335-9F734407-4692-4E30-AEB6-1F64AA65DC0EQ30370672-21A1F597-8D88-41B0-8B7C-F5CD88294EDCQ30536352-A12D69AC-C75D-4A6C-A362-3266ABF2BDD4Q30841365-8869F1AE-8874-4998-8D47-09622AB4CE82Q31133434-EA9EA5D8-BDFF-4B08-8C6D-B3E7BB043D32Q31152172-AF1DABFC-F7F7-4297-9CEE-987CF9027F1AQ33532632-4099C49F-F9F5-4D01-8052-5FE7F61B4444Q33590624-45FB18B3-D591-48FE-AAC2-33287A22EA11Q33628677-949DA048-975C-4CF8-9122-4818C26592C8Q33723804-41A5B359-0175-4445-BC01-23CB924D1B5EQ33960556-838E4910-8601-496A-8C44-11073C9B06F4Q34046881-585A3769-C70F-4BC4-8708-D4D365A54EF1Q34169725-893F26D3-4528-48F3-896B-12E5FCB6C7CEQ34188451-C4ED1E48-ACCE-4B42-ACD8-46784DF05514Q34429685-904AEBC0-5F92-4636-8A25-C590E9A4D6E4Q34451067-3B3775F8-BE52-4A8F-B680-B5706A6A79FFQ35026444-BE8F62DD-8278-4092-A737-7500A6B33649Q35049058-2E6AB8B5-8F9D-4557-A168-06A9ED0F2325Q35124353-0EB0BDBC-3A00-4423-A32A-04FF4C396497Q35203712-7EA88994-685E-41DC-ADEC-E5C6F961BAC5Q35607051-12B6DAC3-E55F-409C-8403-D97BB2AB5E8CQ35756468-9F1F31DF-7827-422F-A62C-7CB827846370Q35773020-8D0B54F0-0ACB-41FB-9EA3-77EC6E9B3A44Q35880875-B8BE0184-91EC-4A6B-80AA-0926F1CBB38CQ36012953-3FEC8252-BD77-4362-AD92-2863F1886925Q36102770-8052BDBF-A7F0-4845-9BFB-DF3EC213A5A7Q36125495-FA42696C-72C4-4D67-AB9F-B4A7FD10D0DCQ36306734-7336C14C-9397-4247-98F6-297CC2838A89
P2860
Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pleiotropic effects of statins ...... n? A meta-regression analysis.
@ast
Pleiotropic effects of statins ...... n? A meta-regression analysis.
@en
Pleiotropic effects of statins ...... n? A meta-regression analysis.
@nl
type
label
Pleiotropic effects of statins ...... n? A meta-regression analysis.
@ast
Pleiotropic effects of statins ...... n? A meta-regression analysis.
@en
Pleiotropic effects of statins ...... n? A meta-regression analysis.
@nl
prefLabel
Pleiotropic effects of statins ...... n? A meta-regression analysis.
@ast
Pleiotropic effects of statins ...... n? A meta-regression analysis.
@en
Pleiotropic effects of statins ...... n? A meta-regression analysis.
@nl
P2093
P1476
Pleiotropic effects of statins ...... n? A meta-regression analysis.
@en
P2093
Brian Smith
Helmut Schrott
Jennifer G Robinson
Nidhi Maheshwari
P304
P356
10.1016/J.JACC.2005.05.085
P407
P577
2005-10-24T00:00:00Z